Zika vaccine efficacy trials could start in 2017

Protective efficacy of Zika vaccine in AG129 mouse model

Zika virus (ZIKV) is a mosquito-borne flavivirus that causes asymptomatic infection or presents only mild symptoms in majority of those infected. However, vaccination for ZIKV is a public health priority due to serious congenital and neuropathological abnormalities observed as a sequelae of the virus infection in the recent epidemics. We have developed an inactivated virus vaccine with the Afri...

Accelerating HIV-1 Vaccine Efficacy Trials

Despite major advances in HIV-1 therapeutics and prevention strategies, the development of a safe and effective prophylactic HIV-1 vaccine will likely be critical for ending the global HIV-1 epidemic. Yet only four HIV-1 vaccine concepts have been tested for clinical efficacy over the past 30 years. In this Commentary, we describe key hurdles facing the HIV-1 vaccine development field and outli...

Trials of Zika vaccine are set to begin in North America.

The first potential vaccine against the Zika virus to be approved for testing in humans is set to begin phase I clinical trials in the United States. The vaccine’s maker, Inovio, of Pennsylvania, is currently completing the paperwork to begin recruitment of 40 volunteers to participate in Philadelphia, Miami, and an undisclosed site in Canada. The first vaccinations are expected within a few we...

Developing a vaccine against Zika

The race to develop a vaccine against Zika began in February 2016, when the unusual clustering of cases of microcephaly and other neurological disorders associated with Zika virus infection led to the declaration of a public health emergency of international concern. When the World Health Organization held its first consultation in March, 14 active vaccine projects had already been announced. T...

Development of a Zika vaccine.